Introduction
============

Osteoporosis has been defined as a systemic disease characterized by low bone mass and disruption of bone architecture resulting in reduced bone strength and an increased relative risk of fracture. The prevalence of osteoporosis is estimated at over 200 million people worldwide ([@b33]). In the US and Europe, about 30% of all postmenopausal women are affected by osteoporosis ([@b33]). As the population ages worldwide, the number of people with osteoporosis is expected to rise correspondingly. Current annual rates of osteoporotic fractures are estimated at around 1.5 million in the US and 3.8 million in Europe ([@b33]). In 1990, the incidence of new hip fractures worldwide was 1.7 million, but this figure is estimated to increase to 2.6 million by 2025 ([@b33]). Direct expenditure related to osteoporotic fractures was US\$17 billion in the US in 2001; in the European Union costs were US\$32 billion in 2000 and are expected to double by 2050 ([@b33]).

Adherence to treatment of osteoporosis
======================================

Treatment to decrease the risk of osteoporotic fractures may include bisphosphonates, raloxifene, teriparatide, estrogen, calcitonin, and strontium ranelate. Despite the proven efficacy of bisphosphonates in reducing both vertebral and non-vertebral fractures, and increasing bone mineral density (BMD), not all patients gain maximum benefit from these therapies. A major reason cited for suboptimal efficacy of oral bisphosphonates is poor long-term adherence to medication therapies, a common feature of chronic disease ([@b38]). Poor adherence can have serious consequences. Studies have shown that patients who do not adhere to their dosing schedule have insufficiently decreased bone resorption ([@b13]), lower treatment-related increases in BMD ([@b16]; [@b39]; [@b34]), and, most importantly, a significantly increased risk of fracture ([@b4]; [@b26]; [@b34]).

Fractures resulting from poor adherence increase direct and indirect medical costs, and mortality ([@b6]; [@b4]; [@b26]). Both patient and medication factors are involved in this major problem, one being the complexity of the dosing regimen ([@b7]; [@b22]) or a complex dosing schedule of therapy ([@b28]; [@b23]; [@b35]).

Due to poor adherence to anti-osteoporotic treatments, maximizing compliance should be a primary focus of clinical management ([@b30]). Newer formulations of bisphosphonates have been developed. Dosing frequency influences compliance. Currently alendronate is available as a daily or weekly therapy and ibandronate is available as a monthly therapy. Risedronate in a daily, weekly, or a twice-monthly dosing regimen (75 mg on 2 consecutive days each month) was recently approved by the US Food and Drug Administration (FDA) ([@b3]; [@b14]; [@b10], [@b12]; [@b29]).

Patients prefer these new dosing formulations ([@b36]; [@b2]; [@b21]) and consequently weekly dosing is associated with better persistence ([@b8]; [@b15]) and compliance ([@b8]; [@b15]; [@b31]) than daily dosing. Proven treatment efficacy, however, is another important factor that affects patient preference ([@b17]; [@b20]; [@b37]). However, adherence rates with weekly regimens are still inadequate. Only 37%--58% of patients who received weekly bisphosphonate therapy remained persistent at 1 year, and just 46%--69% complied correctly ([@b8]; [@b15]; [@b31]). These data suggest a need for simpler and less frequent dosing.

A monthly therapy with vertebral, non-vertebral, and hip fracture reduction efficacy would give physicians another treatment option. At the time of this study ibandronate 150 mg is the only bisphosphonate approved for once-monthly administration. The treatment with monthly oral ibandronate produced significant and progressive increases in lumbar spine (LS) BMD of 4.9% after 1 year in the MOBILE study. Furthermore 150 mg monthly regimen produced similar and significant increases in hip BMD (total hip, femoral neck, and trochanter). Therefore, in women with postmenopausal osteoporosis, monthly ibandronate is at least as effective for BMD endpoints as daily ibandronate ([@b29]). In a previous study daily ibandronate demonstrated a significant reduction of risk of new morphometric vertebral fractures by 50% (p = 0.0006) versus placebo and a statistically significant relative risk reduction in clinical vertebral fractures of 48% was observed, but the incidence of non-vertebral fractures was not significantly reduced. However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score \<3.0 ) ([@b5]).

FDA and European Medicines Agency (EMEA) guidelines have determined that alternative dosage forms can be approved based upon BMD.

Characteristics of risedronate
==============================

Risedronate is a pyridinil bisphosphonate that has been shown in prospective fracture studies to reduce vertebral and non-vertebral fracture risk ([@b18]; [@b32]; [@b24]). Several studies have shown that in patients with postmenopausal osteoporosis, risedronate increases BMD by 5.4%--5.9% in the LS and by 1.6%--3.1% in the femoral neck, and reduces vertebral fractures by 41%--49% and hip fractures by 40% ([@b18]; [@b32]; [@b24]; [@b9]).

For an anti-osteoporotic drug to be administered at extended drug-free intervals and provide persistence of effect, it needs to possess certain properties. These properties include high antiresorptive potency, favorable bone binding characteristics, distribution, concentration, and persistence in bone tissue, and good tolerability. Clinical pharmacology and pharmacokinetic studies, and preclinical animal studies have shown risedronate to possess these characteristics. So, like other bisphosphonates, risedronate remains active on the surface of bone for long periods after dosing, providing the opportunity to develop a range of dosing schedules. Although the original dosing regimen for postmenopausal osteoporosis was an oral dose of 5 mg risedronate daily, it was later demonstrated that 35 mg once a week provided similar efficacy and safety to the daily regimen ([@b3]). Risedronate 75 mg each day for 2 consecutive days a month (2CDM) has also been shown to be effective, and was recently approved by the FDA for the treatment and prevention of postmenopausal osteoporosis ([@b1]; [@b25]; [@b12]).

Efficacy and safety of monthly dosing of 75 mg risedronate on two consecutive days a month
==========================================================================================

This dosing regimen is one of the steps taken towards a once-a-month dosing regimen of 150 mg risedronate. To determine if risedronate 75 mg 2CDM regimen is non-inferior to risedronate 5 mg daily, 1 year of treatment with risedronate 5 mg daily (n = 613) was compared with risedronate 2CDM in a international, phase III, randomized, double-blind, parallel-group multicenter study in postmenopausal women with osteoporosis (n = 616) ([@b11]).

The primary efficacy endpoint was the percentage change from baseline in LS BMD at month 12.

Secondary efficacy measures included mean percentage change from baseline in LS and hip BMD, as well as bone turnover markers (BTMs). In addition, the incidence of new vertebral fractures was determined, based on comparison of X-ray measurements from baseline to month 12.

Non-inferiority in increasing LS BMD was demonstrated with 75 mg 2CDM of risedronate, which represents the same cumulative monthly dose of risedronate (150 mg) as the 5 mg daily dosing regimen (treatment difference 0.21: 95% CI 0.19--0.62). Secondary efficacy analyses similarly showed no clinically relevant differences between the 75 mg 2CDM and the 5 mg daily regimens of risedronate: the mean increases from baseline in LS BMD at 1 year were 3.4% (3.1, 3.7; 95% CI) vs 3.6% (3.3, 3.9; 95% CI), respectively. The results were also similar for mean percentage change from baseline in total hip, trochanter, and femoral neck BMD, and BTMs were significant and similar for both treatments groups.

Although the study did not aim to measure fractures, the incidences of vertebral and non-vertebral fractures were similar in the two treatment groups and, for example, new vertebral fractures occurred after 1 year in only 1% of subjects treated with either risedronate dosing regimen. Treatment efficacy in this study was similar to that in earlier reports with daily or weekly risedronate for both changes in BMD ([@b32]; [@b3]; [@b19]) and BTMs ([@b3]; [@b19]).

Safety and tolerability were good for both risedronate dosing regimens, with comparable overall treatment-emergent adverse effects (TEAEs), TEAEs leading to withdrawal, gastrointestinal (GI) tolerability, fractures, and clinical laboratory data. The most commom TEAEs were arthralgia and back pain in both treatment groups. The incidence of TEAEs potentially associated with acute phase reactions was low in both dosing groups and TEAEs were experienced in a higher number of subjects in the group treated with risedronate 75 mg 2CDM (4 subjects) compared with the group taking 5 mg risedronate daily (0 subjects). Only 9% of subjects in either treatment group discontinued treatment prematurely due to an AE, most commonly GI-related.

In conclusion, risedronate 75 mg 2CDM was non-inferior and was as well tolerated as 5 mg daily in postmenopausal women with osteoporosis.

Efficacy and safety of risedronate 150 mg once a month
======================================================

A recent study has demonstrated comparable efficacy and safety of risedronate 150 mg once-a-month dosing regimen to daily dosing for postmenopausal osteoporosis.

Two years of treatment with risedronate 5 mg daily (n = 538) was compared with once-a-month risedronate (n = 556) in a international, phase III, randomized, double-blind, parallel-group multicenter study in postmenopausal women with osteoporosis. The results for the first year of the study have been published, which is continuing for a second year ([@b12]).

The primary endpoint analysis was a test of non-inferiority comparing the least mean percentage change from baseline in LS BMD in the 150 mg once-a-month and 5 mg daily groups after 12 months. The month 12 measurement or the last postbaseline obtained prior to month 12 was used (last observation carried forward, also referred to as endpoint). This mean percentage change in LS BMD was 3.4% (95% CI 3.03%--3.82%) in the daily group and 3.5% (95% CI 3.15%--3.93%) in the once-a-month group ([Fig. 1](#fig1){ref-type="fig"}) The difference between groups was −0.1% (95% CI −0.51%--0.27%). These results indicated that both groups experienced significant improvement from baseline in LS BMD and that the once-a-month regimen was non-inferior to the daily regimen based on prospectively defined criteria. There was no statistically significant difference between the treatment groups in mean percentage change in LS BMD at any time (ie, month 6, month 12, or endpoint).
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Significant increases from baseline in BMD of sites in the proximal femur (total proximal femur, femoral neck, femoral trochanter) were observed al 6 months and 12 months in both treatment groups. As was the case for LS BMD, there was no statistical difference between treatment groups at any time point at any hip site.

There was no difference between treatment groups in the occurrence of new incident vertebral fracture as determined by morphometric measurement during the first 12 months of treatment.

Significant decreases from baseline in BTMs were observed at 3, 6, and 12 months in both treatment groups and there was no statistically significant difference between treatment groups at endpoint for any of the BTMs.

Both regimens were well tolerated; 9.5% of patients in the daily group withdrew from treatment as a result of an adverse event and 8.6% in the once-a-month group. Adverse events of special interest for bisphosphonates (clinical vertebral and non-vertebral fractures, upper GI, and musculoskeletal) were reported by similar proportions of patients in both treatments groups. Incidence of adverse events, adverse events leading to withdrawal, and upper GI adverse events was similar in both treatment groups.

Most events associated with possible acute phase reactions were determined by the investigator to be mild or moderate in severity; only 1 patient, in the once-a-month group, experienced a severe event. The incidence of symptoms potentially associated with an acute phase reaction, although low in both groups, was slightly higher in the monthly group (1.4%) than in the daily group (0.2%) ([Table 1](#tbl1){ref-type="table"}).

###### 

Summary of adverse events

                                                                                   Risedronate   
  -------------------------------------------------------------------------------- ------------- ------------
  Adverse event                                                                    504 (78.5)    515 (79.2)
  Serious adverse event                                                            27 (4.2)      40 (5.2)
  Deaths                                                                           3 (0.5)       0
  Withdrawn due to an adverse event                                                61 (9.5)      56 (8.6)
  Most common adverse event associated with withdrawal gastrointestinal disorder   36 (5.6)      38 (5.8)
  Most common adverse events                                                                     
   Upper abdominal pain                                                            39 (6.1)      53 (8.2)
   Diarrhea                                                                        30(4.7)       53 (8.2)
   Constipation                                                                    47 (7.3)      38 (5.8)
   Influenza                                                                       27 (4.2)      58 (8.9)
   Arthralgia                                                                      47 (7.3)      36 (5.5)
  Adverse events of special interest                                                             
   Clinical vertebral fracture                                                     4 (0.6)       2 (0.3)
   Non-vertebral fracture                                                          18 (2.8)      13 (2.0)
   Upper gastrointestinal tract adverse effects                                    110 (17.1)    129 (19.8)
  Skeletal adverse events                                                          110 (17.1)    101 (15.5)
  Adverse events potentially associated with acute phase reaction                  1 (0.2)       9 (1.4)

Atrial fibrillation was reported by 3 patients (0.5%) in the 5 mg daily group and 4 patients (0.6%) in the 150 mg once-a-month group. There were no reported cases of osteonecrosis of the jaw.

In conclusion, risedronate 150 mg once a month is similar in efficacy and safety to daily dosing and may provide an alternative for patients who prefer once-a-month oral dosing.

Conclusion
==========

There is growing evidence to show that complex dosing regimens contribute towards suboptimal adherence to bisphosphonates in women with postmenopausal osteoporosis. Several medications have been shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients. Dosing frequency influences compliance; although patients using weekly biphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates are suboptimal. Currently risedronate and alendronate are available as a weekly therapy and ibandronate is available as a monthly therapy.

Risedronate is an oral, nitrogen-containing bisphosphonate that possesses properties that provide easier dosing alternatives for patients, such as strong affinity for bone, potent antiresorptive action, high concentration and persistence in bone tissue, and excellent tolerability. The results of recent clinical trials confirm the viability of less frequent dosing with risedronate, and show these regimens to be well tolerated and effective in the treatment of postmenopausal osteoporosis. The study with risedronate 75 mg 2CDM was one of the steps taken towards a once-a-month dosing of 150 mg risedronate. The 75 mg 2CDM regimen has already been approved by the FDA for the treatment and prevention of postmenopausal osteoporosis.

Risedronate 150 mg once a month is comparable in safety and efficacy to daily dosing in the treatment of postmenopausal osteoporosis. Risedronate 150 mg once a month produces clinical effects similar to those seen with 5 mg daily, including mean percentage change in BMD at the lumbar spine and the hip, bone turnover markers, and morphometric vertebral fractures. These ranges of risedronate dosing options, from daily to weekly to monthly, have the potential to improve patient adherence to therapy, and thereby optimize therapeutic outcomes.
